Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.290
-0.060 (-1.79%)
At close: Sep 25, 2026, 4:00 PM EDT
3.337
+0.046 (1.41%)
After-hours: Sep 25, 2026, 7:30 PM EDT

SAB Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--1.322.2423.960.88
Revenue Growth
---40.94%-90.63%-60.73%10.21%
Gross Profit
-48.27-33.35-28.23-14.28-12.533.69
Operating Income
-71.82-48.95-42.91-38.08-28.92-13.39
Net Income
-21.794.26-34.11-42.19-18.74-17.14
Earnings Per Share
-1.56-0.79-3.68-7.64-4.31-6.30
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
102.6396.5920.7656.5715.0533.21
Total Debt
5.135.954.675.915.938.52
Net Cash (Debt)
97.590.6416.0950.669.1224.69
Net Cash Growth
-463.28%-68.23%455.59%-63.07%450.61%
Net Cash Per Share
2.031.481.749.172.099.03

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-53.94-44.78-34.29-25.12-23.461.99
Capital Expenditures
-3.5-0.93-0.34-0.2-2.17-10.94
Free Cash Flow
-57.44-45.71-34.63-25.32-25.63-8.96
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----52.44%6.07%
Operating Margin
---3244.87%-1700.56%-120.97%-22.00%
Pretax Margin
---2579.03%-1884.50%-78.29%-28.16%
Profit Margin
---2579.03%-1884.50%-78.40%-28.16%
FCF Margin
---2618.65%-1130.71%-107.20%-14.71%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-41.78----
PS Ratio
--26.4828.331.245.58